Saturday, August 5th

3-7pm  CHECK-IN and REGISTRATION  
Conference Office @ 10 Buick St. Room G18


Sunday, August 6th

8.15-8.30am  WELCOME  
C Black and R Lafyatis
Tribute to Joe Korn  
R Simms

8.30-10  Session I – Stem Cell Biology in Vascular and Fibrotic Disease  
Moderator: R Strieter  
Keynote: J Huard - Regenerative medicine based on muscle derived stem cells: Potential for tissue regeneration and repair  
M Kuwana - Circulating endothelial progenitors as a therapeutic target for scleroderma vascular disease  
C Dong - Deficient repair - the culprit of scleroderma vascular lesion formation?

10-10.30  Coffee Break

10.30-12.30pm  Session II – Vascular Disease in Systemic Sclerosis  
Moderator: H Farber  
Keynote: M. Rabinovitch - Infection, Inflammation Mts1 and Pulmonary Hypertension  
K Pritchard - D-4F, an ApoA-I mimetic, decreases inflammation and fibrosis and increases angiogenic responses in the myocardium of tight skin mice  
N Flavahan - The cold facts about peripheral vasospasm  
B Khaw - Molecular Imaging of vascular injury

12.30-1.30  Lunch
1.30-3.30  Breakout Session I
A. Hurdles, networks, funding: Where should we be going? – CGS511
Moderator: S Jimenez/F Arnett
E Gretz – National Institutes of Health
L Evnin – Scleroderma Research Foundation
E Gravallese – Arthritis Foundation
J Blint – Scleroderma Foundation

B. Animal Models – CGS505
Moderator: S Clark/H Gardner
C Denton - Inducible disruption of TGFbeta signalling in fibroblasts in vivo
R Lafyatis – Complex cytokine regulation of Tsk1 pathology
P Christner/J Gentiletti – The fibrotic and immunologic facets of the Tsk2 mouse
C Feghali-Bostwick
S Sonnylal - CTGF overexpressing mice: A model for human scleroderma

3.30-4  Tea Break

4-6  Session III – Inflammation and Vascular Injury
Moderator: B Kahaleh/S Schwartz
Keynote: P Libby - Inflammation and the regulation of arterial extracellular matrix metabolism
O Distler - The impaired angiogenesis in systemic sclerosis
S Schwartz - The vasculopathy of scleroderma
S Jimenez – Role of allograft inflammatory factor 1 (AIF-1) in the pathogenesis of SSc vasculopathy

6-7.30  Welcome Reception – Agganis Arena Burke Club Room
Monday, August 7th

8.30-10.00am  
Session IV – Autoimmune Dysregulation in Systemic Sclerosis  
Moderator: A Marshak-Rothstein  
Keynote: A Rosen - Autoimmunity in scleroderma  
T Radstake - Toll-like receptors in systemic sclerosis, new light on an ancient system!  
T Tedder - Are B lymphocytes contributing to systemic sclerosis pathogenesis?

10-10.30  
Coffee Break

10.30-12.00pm  
Session V – T-cell Regulation and Fibrosis  
Moderator: M Kuwana  
Keynote: R Flavell - Regulation of immunity and autoimmunity by TGFβ  
T MacDonald – Smad 7 control of TGFβ responses in the gut  
C Buckley – Defining a role for fibroblasts in the persistence of chronic inflammation

12-1  
Lunch

1-1.30  
Poster Viewing – 18th Floor Lounge, 10 Buick Street. Authors stand by posters

1.30-3  
Poster Session – Dance Theatre - Top ranking posters orally presented  
Moderator: P Clements  
P Fernandez – Adenosine modulates dermal fibrogenesis  
A Bujor - Akt positively regulates collagen in dermal fibroblasts via a Smad3 independent pathway  
A Ghatnekar - The Role of Gata3 as a regulator of ECM homeostasis in SSc  
A Ghosh - Peroxisome proliferator-activated receptor-y (PPAR-y) inhibits collagen gene expression: implications for Fibrosis  
Y Pare - CD4+ CD8+ double positive (DP) T cells with very high IL-4 production potential are present in lesional skin of systemic sclerosis (SSc) patients
T Rodriguez-Reyna - Rate of skin thickness progression in early systemic sclerosis with diffuse cutaneous involvement: Associations with organ involvement and 5 year survival
D Abraham (V Rajkumar) – PDGFB receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing

3-3.15 Tea break

3.15-4.45 Session VI – Fibrotic Mediators I
Moderator: T MacDonald
Keynote: P ten Dijke - TGFβ receptor signal transduction
M Trojanowska - Fibroblast signaling in scleroderma
J Pearson - Endothelin and fibrosis

5.00-7 Breakout Session II
A. Immunomodulators and Fibrotic Disease – CGS511
Moderator: F Wigley
New therapeutic agents in scleroderma:
  C Denton – Mycophenolate mofetil in diffuse scleroderma
  E Smith – Sirolimus (Rapamycin)
  R Silver - Anti-chemokine therapy (MCP-1/CCR2)
  L Hummers – Intravenous gammaglobulin
  R Lafyatis – Anti-B cell therapy (rituximab)

B. Chronic graft vs. host disease modeling of SSc – CGS505
Moderator: A Gilliam
A Gilliam - Triggers of fibrosing disease in GVHD - why sclerodermatous disease rather than lupus-like epithelial injury?
W Shlomchik - Roles of antigen, antigen presenting cells and naive CD4 cells in murine chronic GVHD
A Aliprantis - The role of T-bet in scleroderma and the molecular phenotype of murine chronic GVHD
Tuesday, August 8th

8.30-10.30am Session VII – Tissue Fibrosis: Cellular Pathogenesis
Moderator: J Varga
T Krieg - Mechanism of fibroblast activation and the role of cell matrix contacts
S Phan - Transcriptional regulation of myofibroblast differentiation
H Chang - Site specific differentiation and positional memory of fibroblasts
E Leof - TGF-beta signaling targets in fibrotic diseases

10.30-11 Coffee Break

11-12.30pm Session VIII – Fibrotic Mediators
Moderator: D Abraham
D Brigstock - Connective tissue growth factor: Structure, function, and role in fibrosis
K Lyons - In vivo studies of CCN1/Cyr61 and CCN2/CTGF function in connective tissues and vasculature
J Bonner - PDGF Signaling in Chronic Airway Remodeling and Fibrosis

12.30-1.30 Lunch

2-4 Session IX – Pulmonary Fibrosis/Pathogenesis
Moderators: A Wells/K Brown
Keynote: J Elias - Transgenic investigations of Th2 and TGF-beta1-induced tissue fibrosis
V Thannickal - Novel insights into myofibroblast activation and survival
N Kaminski - Microarray analysis of Human Lung Fibrosis - from profiles to pathways
R Strieter - The role of circulating mesenchymal progenitor cells in pulmonary fibrosis

4-4.30 Tea Break
4.30-6.30 Breakout Session III – CGS511
A. How do we block TGFβ in scleroderma?
Moderator: M Trojanowska
S Violette - The alphavbeta6 integrin: A novel therapeutic target for lung and kidney fibrosis
A Protter - TBA
J McPherson - Progress in the clinical development of anti-TGF-beta antibodies for the treatment of fibrotic diseases

B. Gene expression profiles, what do they tell us? – CGS505
Moderator: C Feghali-Bostwick
M Whitfield - Molecular portraits of scleroderma skin
F Tan - The next step after differential gene expression
H Gardner - Gene profiling in SSc: Fibroblasts forget where they came from and other results

7-9 BANQUET – Agganis Arena Burke Club Room
Speaker: Dr. Don Berwick

Wednesday, August 9th

8.30-10.30am Session X – Pulmonary Fibrosis/Clinical
Moderator: R Du Bois
Keynote: A Wells - Pulmonary fibrosis in scleroderma: How clinical science can refine management
J Goldin - Quantitative Image Analysis of HRCT: predictor and measure of treatment efficacy
J Seibold - Clinical applications of endothelin antagonists in scleroderma
K Brown - Pulmonary fibrosis: Clinical insights into disease mechanism

10.30-10.45 Coffee Break
10.45-12.30pm  Session XI – Genetic Analyses in Scleroderma  
Moderator: F Arnett  
Keynote: M Seldin - Understanding and application of population genetic structure to problems in medicine and autoimmunity  
M Mayes - Scleroderma genetics: Where we are and where we want to be  
R Du Bois - Genetics of lung fibrosis: It's all in the genotype  
K Welsh - Scleroderma genetics worldwide: One disease, many incorrect papers- or many diseases? Do we have or can we get the answer?

12.30-1.30  Lunch

1.30-3.30  Session XII– Outcome Measures  
Moderator: M Matucci-Cerinic  
A Tyndall - Report from the EUSTAR Minimal Essential Data Set (MEDS) data base  
D Furst - Progress at OMERACT toward combined measures of response in SSc: Renal disease, pulmonary disease and early efforts at a combined index of response  
D Khanna - Patient-reported outcomes in scleroderma  
P Merkel – Outcome measures for scleroderma clinical trials: A data-driven re-evaluation